Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough...
BELLUS Santé inc. (Nasdaq : BLU; TSX : BLU) (« BELLUS Santé » ou la « société »), une société biopharmaceutique au stade clinique qui développe de nouveaux produits thérapeutiques pour le...
- Announced positive topline results from the Phase 2b SOOTHE clinical trial in refractory chronic cough (“RCC”), positioning BLU-5937 as a potentially best-in-class P2X3 antagonist - - Plans to...
BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
| 4 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
| 12 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
| 26 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
| 52 | 0 | 0 | 19.48 | 19.48 | 19.48 | 0 | 0 | CS |
| 156 | 9.35 | 92.3000987167 | 10.13 | 19.9 | 6.3 | 56963 | 12.3196534 | CS |
| 260 | 10.49 | 116.685205784 | 8.99 | 19.9 | 2.7 | 97686 | 8.61620722 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
